Donation

Series
Dr Saemundur Rognvaldsson ASH abstract on MGUS

Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from iStopMM

February 1, 2023
ASH
Dr Jesus Berdeja ASH abstract on BMS-986393

Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM

February 1, 2023
ASH
Dr. Nizar Bahlis ASH abstract on MagnetisMM-3

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3

January 30, 2023
ASH
Dr. Noopur Raje ASH abstract MagnetisMM-1

Elranatamab Induces Durable Responses for Patients with Relapsed or Refractory Multiple Myeloma

January 28, 2023
ASH
Dr. Ashley Rosko on factors that influence transplant and survival

Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race

January 27, 2023
ASH
Dr. Tondre Buck abstract on race and myeloma risk assessment

Real-World Multiple Myeloma Risk Factors and Outcomes By Race/Ethnicity in the United States

January 16, 2023
ASH
Dr. Ajai Chari abstract on MonumenTAL-1

Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1

January 12, 2023
ASH
Dr. Saad Usmani abstract on KarMMa2

KarMMa2: Efficacy and Safety of Idecabtagene Vicleucel in High Risk Multiple Myeloma Pts with Early Relapse after ASCT

January 12, 2023
ASH
Dr Gary Schiller ASH abstract on Selinexor

Once Weekly Selinexor, Carfilzomib and Dexamethasone in Triple Class Refractory Multiple Myeloma

January 10, 2023
ASH
Dr. Long abstract on MGUS and CKD as part of the iStopMM study

MGUS and Risk of Chronic Kidney Disease: Results of the Population-Based iStopMM Study

January 2, 2023
ASH
Dr. Sigrun Thorsteinsdottir abstract on CTPC and Smoldering Multiple Myeloma

Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma Cohort

January 2, 2023
ASH
Dr. Noemi Puig on NGF vs Mass Spec

Clinical Impact of NGF in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess MRD in Newly Diagnosed Multiple Myeloma Pts Receiving Maintenance

December 27, 2022
ASH

Give Where Most Needed

Learn More